Mr. Liang leads Brii Biosciences’ business in China, including Medical Affairs, Regulatory Affairs, Government Affairs, Commercialization and Operations.

Mr. Liang has more than 20 years of experience in the pharmaceutical and biotechnology industries with a background that spans medical affairs and commercialization across multiple therapeutic areas. Throughout his decades-long career, he has held high-level positions at several multi-national companies and has worked extensively in the hepatitis space in particular, acquiring in-depth knowledge and insights of the unmet needs that exist for patients and healthcare providers alike.

Previously, Mr. Liang held the role of Vice President of Scientific and Medical Affairs at Brii Bio, where he oversaw external scientific engagement with KOLs, medical associations and patient communities, and also served as an effective and compelling leader. Prior to joining Brii, he was Executive Director at Gilead China, where he successfully launched eight innovative brands in HBV, HCV and HIV, and built high performing commercial teams to establish strong foundations for long-term business growth. Mr. Liang also worked at notable industry giants such as Amgen, Novartis, Roche, and AbbVie, where he developed a successful record of integrating patient unmet needs and scientific evidence into meaningful product portfolios. Before his career in the drug development industry, Mr. Liang spent five years as a physician at Beijing Fuxing Hospital.

Mr. Liang obtained his Master degree in Marketing from Macquarie University in Australia, and his Bachelor degree in Clinical Medicine is from the Capital University of Medicine Science in China.